Skip to content
Collagen & skinbest peptide serum

Best Peptide Serum: How to Choose One on Evidence

Which peptide, at what concentration, in a formula that makes sense, at what price per mL. The criteria that matter when the marketing all sounds identical.

Sebastian Hunter, Founder and EditorWritten bySebastian Hunter, Founder and Editor

Heads up: this page contains affiliate links, and we may earn a commission if you buy through one - at no extra cost to you. It never changes what the evidence section says. How we handle this.

Start here

Plain English

Choosing a peptide serum comes down to which peptide it uses, at what concentration, in a formula that is plausible for skin. A peptide name on a label is a starting point rather than a result, so we give you the criteria instead of a fixed ranking.

  • Ingredient lists and concentrations matter more than buzzwords.
  • Evidence quality varies wildly by peptide and product.
  • Patch-test new actives; cosmetics still irritate some people.

We are not going to hand you a number one pick and pretend it is settled.

Peptide serums are a large category built on a small pile of human evidence, much of it funded by the people selling the ingredient. One peptide - palmitoyl pentapeptide-4, sold as Matrixyl - has a real placebo-controlled trial behind it. The most famous, copper tripeptide GHK-Cu, has weaker published human data than almost any reader expects. Everything else sits between “mechanistically interesting” and “unstudied on skin”.

So this page gives you the five questions that separate a defensible peptide serum from an expensive one, and tells you where the evidence runs out.

Limited human data

Small or uncontrolled human studies. Too little to settle the question either way. One 12-week placebo-controlled split-face trial of palmitoyl pentapeptide-4 (n=93, industry-authored) and one 4-week controlled trial of acetyl hexapeptide (n=60). A 2026 meta-analysis of 19 peptide RCTs included only two topical trials; the other 17 were oral collagen peptides.

US legal status - Cosmetic

Regulated as a cosmetic in the US. Cosmetics are not FDA-approved before sale, and may only make appearance claims - a product claiming to change the structure or function of skin is making a drug claim.

The five criteria

1. Which peptide, named on the label

Lupo 2007 - Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-9. (opens PubMed in a new tab) put it plainly: there are three main categories of cosmeceutical peptides - signal, neurotransmitter-affecting, and carrier. A fourth class, enzyme-inhibiting, comes from later reviews; Badilli 2025 - Badilli U, Inal O. Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers. Polymers (Basel). 2025;17(6). (opens PubMed in a new tab) describes these as peptides that inhibit enzymes such as MMPs, and notes the work is predominantly in vitro.

The taxonomy in Errante 2020 - Errante F, Ledwoń P, Latajka R et al. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. (opens PubMed in a new tab) is the one to shop with:

  • Carrier - copper tripeptide-1 (GHK-Cu) and manganese tripeptide-1. Exactly two.
  • Signal - palmitoyl pentapeptide-4 (Matrixyl), PKEK, GEKG, tripeptide-10 citrulline.
  • Neurotransmitter-inhibiting - acetyl hexapeptide-3 (Argireline), pentapeptide-3 (Vialox), pentapeptide-18, SNAP-8.

That review notes there are no further investigations directly describing or enhancing the anti-wrinkle properties of Vialox - which should change how you read a label listing six peptides. The number of peptides in a formula is not evidence. It is copy.

2. Concentration, compared against what was tested

This is where most serums fail, quietly. The strongest human trial in the category is Robinson 2005 - Robinson LR, Fitzgerald NC, Doughty DG et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-60. (opens PubMed in a new tab): palmitoyl pentapeptide-4 at 3 parts per million, 93 Caucasian women aged 35–55, 12 weeks, double-blind, placebo-controlled, split-face. It reported significant improvement versus placebo for reduction in wrinkles and fine lines, by both quantitative technical and expert grader image analysis. The listed affiliation is Procter & Gamble’s Miami Valley Laboratories - worth knowing, not disqualifying. It remains a genuine peer-reviewed, split-face, placebo-controlled trial, which is a study category GHK-Cu entirely lacks.

Three ppm is a tiny concentration. “High-strength peptide” marketing is not obviously better; it is simply untested. What you want is a brand that states its peptide percentage at all. Most do not.

3. Is the formula plausible?

Two sub-questions, and we have to be careful about how much either is actually known.

Penetration. GHK’s molecular weight is 340.38 Da, under the threshold in the proposed 500 Dalton rule (Bos 2000 - Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-9. (opens PubMed in a new tab)) - but that rule is a heuristic argued from three lines of circumstantial evidence, not a physical limit. GHK’s computed properties cut the other way: an XLogP of −4.4 and a topological polar surface area of 176 Ų make it extremely hydrophilic and highly polar, and it is charged at skin pH. The stratum corneum is a lipophilic barrier. Whether that stops GHK crossing it in a real formula is an inference; we found no source measuring it.

Where permeation has been examined head-on, the literature contradicts itself. Zdrada-Nowak 2025 - Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025;26(12). (opens PubMed in a new tab) records two flatly contradictory results for acetyl hexapeptide-8: one study reporting around 30% of an applied 10% formulation penetrating a membrane in two hours, another finding only 0.22% penetrating the stratum corneum at 24 hours with none detected in receptor solution. Its authors conclude that AH-8’s ability to reach neuromuscular junctions remains uncertain, and that transdermal delivery sufficient to paralyse muscle is likely impossible. The review declared no external funding.

Incompatibilities. You have read that copper peptides must never touch vitamin C. What is actually known: the published literature indexes no clinical or in vivo studies of GHK-Cu and vitamin C applied to skin together, and that null holds across several search formulations. The caution is not pure folklore - copper-catalysed ascorbate oxidation is real solution chemistry, and there is older in vitro work finding that ascorbate plus a copper-tripeptide complex cleaves DNA and proteins when neither does so alone. We could not verify a primary source for either point against our citation registry, so treat both as background rationale rather than as findings we have checked for you.

One thing cuts against a confident warning: GHK-Cu is a chelate. The copper is bound to the peptide rather than free, and chelation materially alters copper’s redox behaviour - so extrapolating free-copper solution chemistry to GHK-Cu on skin is an inference, not a finding. No study has measured this for GHK-Cu specifically.

4. Packaging

Prefer opaque, airless pumps over dropper bottles and jars. To be straight about the basis: that is standard formulation practice, not something our sources measured for peptides. We found no primary study on peptide serum stability in different packaging. Preferring the airless pump costs nothing - just don’t pay a premium for it as though it were proven.

5. Price per mL

Do the division. A 15 mL serum at $90 is $6.00/mL; a 30 mL serum at $120 is $4.00/mL. Given that the best-supported concentration in the literature is 3 ppm, price tracks brand and packaging far more than active ingredient. No evidence says expensive peptide serums outperform cheap ones, because nobody has run that trial.

The GHK-Cu problem

GHK-Cu is the peptide most readers arrive looking for, and the one where the gap between reputation and evidence is widest.

Loren Pickart isolated GHK in 1973 as an activity in human albumin that caused old human liver tissue to synthesize proteins like younger tissue (Pickart 2015 - Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. (opens PubMed in a new tab)). Pickart 2008 - Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88. (opens PubMed in a new tab) proposes four mechanisms - recruitment of repair cells, anti-inflammatory action via free radical suppression, stimulation of collagen, elastin and growth factor synthesis, and enhanced fibroblast and keratinocyte proliferation. That is the originator’s framework, not replicated consensus.

Then the awkward parts:

None of that proves GHK-Cu does nothing. It means the evidence is small, old, non-peer-reviewed or industry-linked - largely untested to modern standards. We found no independent, non-industry group that has replicated topical GHK-Cu efficacy in a controlled trial.

What the pooled evidence actually covers

The 2026 meta-analysis (Nukaly 2026 - Nukaly HY, Halawani IR, Irtaza HM et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2026;13:1618306. (opens PubMed in a new tab)) is the best pooled summary we have, and the first thing to say about it is that it is mostly not about topical peptides at all: 17 of its 19 trials were oral collagen peptides or hydrolysates, covering 1,236 of the 1,341 participants - 92% of everyone studied. The topical arm was two studies, one of Argireline and one of alpha-defensin-5/beta-defensin-3. Neither Matrixyl nor GHK-Cu was tested in any included trial.

For comparison: a 2022 systematic review of topical tretinoin (Sitohang 2022 - Sitohang IBS, Makes WI, Sandora N et al. Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials. Int J Womens Dermatol. 2022;8(1):e003. (opens PubMed in a new tab)) covered 7 randomized trials and 739 subjects, reporting that all studies consistently found tretinoin efficacious for the clinical appearance of photoaging - in wrinkling, mottled hyperpigmentation, sallowness and lentigines - with improvements appearing after 4 months and persisting to 24 months, across concentrations of 0.025%–5%.

That is the shape of the decision. Peptides are adjuncts. A retinoid is the intervention.

Our picks

Buyer’s guide

For the peptide with the best human trial behind it, look for palmitoyl pentapeptide-4 (Matrixyl), and check whether the brand discloses a concentration.

If you want a wrinkle-relaxing peptide, acetyl hexapeptide-3 (Argireline) has a randomized placebo-controlled trial in 60 Chinese subjects, twice-daily peri-orbital, 4 weeks (Wang 2013 - Wang Y, Wang M, Xiao S et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-53. (opens PubMed in a new tab)): total anti-wrinkle efficacy of 48.9% versus 0% in placebo, with reduced roughness (p < 0.01). That is one small 4-week trial, and the permeation review above suggests it may not reach the target it is theorized to act on.

If you specifically want GHK-Cu, buy it knowing the evidence picture above. It is not supported by the human data people assume it has.

If your goal is photoaging, the trial evidence favors a retinoid over a peptide serum by a wide margin.

If marketing says a peptide modulates thousands of genes, the figure is widely repeated but we could not verify any primary source for it. It traces to gene-expression signature work in cultured cells, restated across the ingredient proponent’s own review series - not to a skin outcome. Treat it as an unsourced number until someone produces the measurement behind it.

What we could not answer

  • Whether GHK-Cu penetrates intact human skin in a finished formula. The molecular weight is permissive, the polarity is not, and we found no measurement.
  • Whether GHK-Cu and vitamin C interact on skin. Untested either way.
  • Whether packaging changes peptide serum stability. Plausible, unmeasured in our sources.
  • Whether any finished serum outperforms any other. No head-to-head trials exist.
  • What concentration of GHK-Cu, at what pH, is needed for any effect. Products range widely with no human dose-response data.

If that reads as a lot of “we don’t know”, that is the accurate state of the field.

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.

  1. 1.Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-9.ReviewPMID 10839713
  2. 2.Robinson LR, Fitzgerald NC, Doughty DG et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-60.StudyPMID 18492182
  3. 3.Wang Y, Wang M, Xiao S et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-53.Randomised trialPMID 23417317
  4. 4.Miller TR, Wagner JD, Baack BR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9.Randomised trialPMID 16847171
  5. 5.Nukaly HY, Halawani IR, Irtaza HM et al. Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne). 2026;13:1618306.Systematic reviewPMID 41924746full text
  6. 6.Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.ReviewPMID 26236730full text
  7. 7.Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008;19(8):969-88.ReviewPMID 18644225
  8. 8.Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-9.ReviewPMID 18045359
  9. 9.Errante F, Ledwoń P, Latajka R et al. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923.ReviewPMID 33195061full text
  10. 10.Badilli U, Inal O. Current Approaches in Cosmeceuticals: Peptides, Biotics and Marine Biopolymers. Polymers (Basel). 2025;17(6).ReviewPMID 40292641full text
  11. 11.Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025;26(12).ReviewPMID 40565185full text
  12. 12.Sitohang IBS, Makes WI, Sandora N et al. Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials. Int J Womens Dermatol. 2022;8(1):e003.ReviewPMID 35620028full text
  13. 13.PubChem Compound Summary CID 73587 (GHK) - computed physicochemical properties- National Library of Medicinedatabase
  14. 14.21 U.S.C. §321 - FD&C Act definitions of 'cosmetic' (§321(i)) and 'drug' (§321(g)(1))- Legal Information Institute, Cornell Law Schoolstatute

Keep reading

Related guides